Resistance development profiling of piperacillin in combination with the novel -lactamase inhibitor BLI-489

Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.

The in vivo efficacy of piperacillin in combination with the penem inhibitor BLI-489 was determined using acute lethal systemic infections in mice. On the basis of preliminary results with various ratios, a dosing ratio of 8:1 was found to be optimal for retention of enhanced efficacy. Piperacillin-BLI-489 dosed at an 8:1 ratio was efficacious against murine infections caused by class A (includ...

Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.

Clavulanic acid and a penicillanic acid sulfone, when combined individually with piperacillin, synergistically inhibited various Enterobacteriaceae, Staphylococcus aureus, and Bacteroides fragilis. Clavulanic acid and piperacillin synergistically inhibited 91 of 170 (55%) isolates tested. Synergy was most often found against piperacillin-resistant bacteria: 65 of 69 isolates (94%). Although the...

AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling

azerbaijans political development after the collapse of soviet union and implication on relation with the islamic republic of iran

در فصل اول این پایاین نامه در خصوص تاریخ کشور اذربایجان قبل و بعد از جدایی این کشور از ایران مورد بررسی قرار گرفته است ودر فصل دوم تحولات سیاسی این کشور بعد از 1991 و در واقع بعد از فروپاشی شوروی و دولتهایی که روی کار امدند در از جمله دولت ابولفضل ایلچی بیگ،دولت حیدر علی اف وبعد از او پسرش الهام علی اف و نگرش هرکدام از این دولتها به سیاسیت خارجی اذربایجان مورد اشاره قرار گرفته است.در ودر فصل سو...

The Novel β-Lactamase Inhibitor, ETX-2514, in Combination with Sulbactam Effectively Inhibits Acinetobacter baumannii

Methods. From January 2011 to December 2016, inclusive, 12 to 15 sentinel hospitals across Canada submitted clinical isolates from patients attending ERs, medical and surgical wards, hospital clinics, and ICUs (CANWARD). Each center was asked to annually submit clinical isolates (consecutive, one per patient/infection site) from blood (100), respiratory (100), urine (25), and wound (25) infecti...